Contribute Try STAT+ Today

And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is rather modest. We hope to hang with a couple of short people, eat some fun food, promenade with the official mascot, and take several naps. And what about you? This is a fine time to enjoy the great outdoors. If vaccinated, you may want to spend time with folks you have missed this past year. Or you could engage in some spring cleaning. Well, whatever you do, have a grand time. But be safe. Enjoy, and see you soon. …

The Johnson & Johnson (JNJ) vaccine could be back in circulation this weekend — albeit with possible restrictions — depending on a recommendation Friday by a federal advisory panel, The Wall Street Journal notes. J&J vaccine injections were put on hold last week after reports of rare blood-clot conditions in a handful of recipients, including one fatality. Many public health authorities, however, contend that the benefits of the vaccine outweigh the risks.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.